BMRN logo

BioMarin Pharmaceutical (BMRN) Cash and cash equivalents

annual cash & cash equivalents:

$942.84M+$187.72M(+24.86%)
December 31, 2024

Summary

  • As of today (June 21, 2025), BMRN annual cash & cash equivalents is $942.84 million, with the most recent change of +$187.72 million (+24.86%) on December 31, 2024.
  • During the last 3 years, BMRN annual cash & cash equivalents has risen by +$355.57 million (+60.54%).
  • BMRN annual cash & cash equivalents is now at all-time high.

Performance

BMRN Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMRNbalance sheet metrics

quarterly cash & cash equivalents:

$1.05B+$105.96M(+11.24%)
March 31, 2025

Summary

  • As of today (June 21, 2025), BMRN quarterly cash & cash equivalents is $1.05 billion, with the most recent change of +$105.96 million (+11.24%) on March 31, 2025.
  • Over the past year, BMRN quarterly cash & cash equivalents has increased by +$301.81 million (+40.40%).
  • BMRN quarterly cash & cash equivalents is now at all-time high.

Performance

BMRN quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMRNbalance sheet metrics

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

BMRN Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+24.9%+40.4%
3 y3 years+60.5%+73.2%
5 y5 years+115.5%+120.0%

BMRN Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+60.5%at high+80.8%
5 y5-yearat high+115.5%at high+120.0%
alltimeall timeat high+9930.2%at high>+9999.0%

BMRN Cash and cash equivalents History

DateAnnualQuarterly
Mar 2025
-
$1.05B(+11.2%)
Dec 2024
$942.84M(+24.9%)
$942.84M(+39.6%)
Sep 2024
-
$675.45M(-30.5%)
Jun 2024
-
$972.15M(+30.1%)
Mar 2024
-
$747.00M(-1.1%)
Dec 2023
$755.13M(+4.2%)
$755.13M(-3.9%)
Sep 2023
-
$785.41M(+13.1%)
Jun 2023
-
$694.38M(+19.7%)
Mar 2023
-
$580.07M(-19.9%)
Dec 2022
$724.53M(+23.4%)
$724.53M(-4.9%)
Sep 2022
-
$761.51M(+22.9%)
Jun 2022
-
$619.80M(+2.4%)
Mar 2022
-
$605.44M(+3.1%)
Dec 2021
$587.28M(-9.5%)
$587.28M(-4.8%)
Sep 2021
-
$617.14M(-3.8%)
Jun 2021
-
$641.53M(-3.9%)
Mar 2021
-
$667.31M(+2.8%)
Dec 2020
$649.16M(+48.4%)
$649.16M(-36.1%)
Sep 2020
-
$1.02B(+24.0%)
Jun 2020
-
$818.90M(+71.8%)
Mar 2020
-
$476.63M(+9.0%)
Dec 2019
$437.45M(-11.4%)
$437.45M(+3.4%)
Sep 2019
-
$423.22M(+37.6%)
Jun 2019
-
$307.58M(-15.6%)
Mar 2019
-
$364.37M(-26.2%)
Dec 2018
$493.98M(-17.4%)
$493.98M(-44.0%)
Sep 2018
-
$882.18M(+106.4%)
Jun 2018
-
$427.41M(-9.8%)
Mar 2018
-
$473.98M(-20.7%)
Dec 2017
$598.03M(+46.5%)
$598.03M(+38.6%)
Sep 2017
-
$431.40M(+21.6%)
Jun 2017
-
$354.86M(+1.9%)
Mar 2017
-
$348.23M(-14.7%)
Dec 2016
$408.33M(+2.8%)
$408.33M(-42.3%)
Sep 2016
-
$707.35M(+131.2%)
Jun 2016
-
$305.97M(+13.1%)
Mar 2016
-
$270.45M(-31.9%)
Dec 2015
$397.04M(-54.6%)
$397.04M(+5.5%)
Sep 2015
-
$376.35M(-14.6%)
Jun 2015
-
$440.66M(-51.1%)
Mar 2015
-
$900.57M(+2.9%)
Dec 2014
$875.49M(+53.9%)
$875.49M(+120.0%)
Sep 2014
-
$398.00M(-31.9%)
Jun 2014
-
$584.72M(-8.6%)
Mar 2014
-
$639.78M(+12.5%)
Dec 2013
$568.78M(+215.1%)
$568.78M(+213.3%)
Sep 2013
-
$181.56M(+3.5%)
Jun 2013
-
$175.44M(+13.6%)
Mar 2013
-
$154.38M(-14.5%)
Dec 2012
$180.53M(+290.1%)
$180.53M(-0.4%)
Sep 2012
-
$181.33M(+2.0%)
Jun 2012
-
$177.76M(+115.2%)
Mar 2012
-
$82.59M(+78.5%)
DateAnnualQuarterly
Dec 2011
$46.27M(-47.5%)
$46.27M(-35.1%)
Sep 2011
-
$71.25M(-36.9%)
Jun 2011
-
$112.96M(+24.4%)
Mar 2011
-
$90.78M(+3.1%)
Dec 2010
$88.08M(-47.3%)
$88.08M(-30.9%)
Sep 2010
-
$127.54M(+10.2%)
Jun 2010
-
$115.78M(+6.3%)
Mar 2010
-
$108.96M(-34.8%)
Dec 2009
$167.17M(-25.0%)
$167.17M(-12.8%)
Sep 2009
-
$191.78M(-4.1%)
Jun 2009
-
$200.05M(-6.8%)
Mar 2009
-
$214.58M(-3.7%)
Dec 2008
$222.90M(-2.4%)
$222.90M(-17.8%)
Sep 2008
-
$271.22M(+7.5%)
Jun 2008
-
$252.21M(-21.2%)
Mar 2008
-
$319.99M(+40.1%)
Dec 2007
$228.34M(+156.1%)
$228.34M(-21.8%)
Sep 2007
-
$291.82M(+42.3%)
Jun 2007
-
$205.01M(+108.5%)
Mar 2007
-
$98.33M(+10.3%)
Dec 2006
$89.16M(+134.1%)
$89.16M(-53.5%)
Sep 2006
-
$191.78M(-32.9%)
Jun 2006
-
$285.99M(-16.3%)
Mar 2006
-
$341.69M(+797.0%)
Dec 2005
$38.09M(+191.2%)
$38.09M(-32.2%)
Sep 2005
-
$56.21M(+228.5%)
Jun 2005
-
$17.11M(+52.2%)
Mar 2005
-
$11.25M(-14.0%)
Dec 2004
$13.08M(-89.2%)
$13.08M(-62.6%)
Sep 2004
-
$34.98M(-27.5%)
Jun 2004
-
$48.25M(-49.8%)
Mar 2004
-
$96.20M(-20.8%)
Dec 2003
$121.41M(+260.9%)
$121.41M(-35.4%)
Sep 2003
-
$187.98M(-15.2%)
Jun 2003
-
$221.77M(+76.2%)
Mar 2003
-
$125.83M(+274.1%)
Dec 2002
$33.64M(+168.5%)
$33.64M(+3.8%)
Sep 2002
-
$32.41M(+67.4%)
Jun 2002
-
$19.36M(+6.4%)
Mar 2002
-
$18.20M(+45.3%)
Dec 2001
$12.53M(-24.2%)
$12.53M(+73.3%)
Sep 2001
-
$7.23M(-61.9%)
Jun 2001
-
$18.97M(-3.8%)
Mar 2001
-
$19.72M(+19.3%)
Dec 2000
$16.53M(-29.4%)
$16.53M(+2.7%)
Sep 2000
-
$16.10M(+51.7%)
Jun 2000
-
$10.61M(-73.9%)
Mar 2000
-
$40.67M(+73.7%)
Dec 1999
$23.41M(+149.1%)
$23.41M(-28.2%)
Sep 1999
-
$32.60M(+89.5%)
Jun 1999
-
$17.20M(+377.8%)
Mar 1999
-
$3.60M
Dec 1998
$9.40M
-

FAQ

  • What is BioMarin Pharmaceutical annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical?
  • What is BioMarin Pharmaceutical annual cash & cash equivalents year-on-year change?
  • What is BioMarin Pharmaceutical quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for BioMarin Pharmaceutical?
  • What is BioMarin Pharmaceutical quarterly cash & cash equivalents year-on-year change?

What is BioMarin Pharmaceutical annual cash & cash equivalents?

The current annual cash & cash equivalents of BMRN is $942.84M

What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical?

BioMarin Pharmaceutical all-time high annual cash & cash equivalents is $942.84M

What is BioMarin Pharmaceutical annual cash & cash equivalents year-on-year change?

Over the past year, BMRN annual cash & cash equivalents has changed by +$187.72M (+24.86%)

What is BioMarin Pharmaceutical quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of BMRN is $1.05B

What is the all time high quarterly cash & cash equivalents for BioMarin Pharmaceutical?

BioMarin Pharmaceutical all-time high quarterly cash & cash equivalents is $1.05B

What is BioMarin Pharmaceutical quarterly cash & cash equivalents year-on-year change?

Over the past year, BMRN quarterly cash & cash equivalents has changed by +$301.81M (+40.40%)
On this page